Cereblon protein now keeps hope in fight against multiple myeloma Research on the same proteins that was a primary mediator of the birth defects due to thalidomide now holds hope in the fight against multiple myeloma, express Mayo Clinic researchers who have presented results of several clinical trials in the 53nd annual conference of the American Society of Hematology Dec. 10-13 in San Diego. The drug thalidomide accomplished infamy in the early 1960s as the cause of serious birth defects after being given to pregnant mothers for morning hours sickness nolvadex-uk.com/how-to-treat-gyno-with-tamoxifen . However, this medication, along with the highly related substances , assists treat blood cancers also, and is used world-wide as a cornerstone of therapy for the bone marrow cancer multiple myeloma.

Cetuximab can fight cancer and prolong existence in many sufferers with advanced colorectal cancer Cetuximab, known as Erbitux also, can battle tumor and prolong life in many patients with advanced colorectal cancers who have exhausted all the treatments, according to research presented at the 2005 Annual Meeting of the American Culture of Clinical Oncology. Actually in individuals who have gone through six or more previous classes of chemotherapy, cetuximab, may fight the development of cancer, giving individuals additional months of lifestyle, says study presenter Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center.